Answers are grounded in this paper and cite their sources.
Docetaxel (DTX) resistance and heterogeneous patient responses limit its clinical benefit in gastric cancer (GC). Although drug-induced adaptive survival programs drive therapeutic resistance, whether DTX activates such programs and how they are regulated remain unclear. Here, we investigated Ras association domain family member 10 (RASSF10), a tumor suppressor frequently epigenetically silenced, as a regulator of DTX sensitivity. Integrated analyses of neoadjuvant/conversion therapy cohorts, patient-derived organoids, and multi-omics datasets showed reduced RASSF10 expression in DTX non-responders and associations with poorer clinical outcomes. RASSF10 sensitized GC cells to DTX by suppressing stress-induced autophagy and lipid metabolic reprogramming. Mechanistically, RASSF10 recruited the E3 ligase F-box and WD repeat domain-containing 11 (FBXW11) to promote K48-linked ubiquitination and proteasomal degradation of Wiskott-Aldrich syndrome protein and SCAR homologue 1 (WASH1) at lysine 220, a process enhanced by DTX exposure. RASSF10 loss stabilized WASH1, promoting WASH1-dependent endosomal trafficking of autophagy-related 9A (ATG9A) cluster of differentiation 36 (CD36) to support autophagosome biogenesis and lipid droplet formation, respectively. Plasma RASSF10 promoter methylation showed potential as an exploratory biomarker for DTX response, and cyclic arginine-glycine-aspartic acid (cRGD)-modified liposomal recombinant RASSF10 improved DTX response preclinically. These findings identify RASSF10 as a regulator of DTX-induced adaptive autophagy and lipid metabolic reprogramming in GC and support its potential as both an exploratory biomarker and a therapeutic sensitization strategy.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: